4.7 Article

Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

期刊

CLINICAL INFECTIOUS DISEASES
卷 51, 期 -, 页码 S81-S87

出版社

OXFORD UNIV PRESS INC
DOI: 10.1086/653053

关键词

-

资金

  1. AB Bioisk
  2. Abbott
  3. Anacor
  4. API
  5. Arpida
  6. Astellas
  7. Avexa
  8. Bayer
  9. bioMerieux
  10. Cadence
  11. Calixa
  12. Cempra
  13. Cerexa
  14. Cornerstone
  15. Cubist
  16. Daiichi
  17. Elan
  18. Elanco
  19. Enanta
  20. GlaxoSmithKline
  21. Johnson & Johnson (Ortho McNeil)
  22. Merck
  23. Nabriva
  24. Novartis
  25. Novexel
  26. Optimer
  27. Ordway
  28. Osmotics
  29. Pacific Beach
  30. Peninsula
  31. Pfizer
  32. Protez
  33. Schering-Plough
  34. Shionogi
  35. Targanta (The Medicines Co)
  36. Theravance
  37. TREK Diagnostics
  38. ViroPharma
  39. Wyeth
  40. US Food and Drug Administration
  41. Infectious Diseases Society of America
  42. American College of Chest Physicians
  43. American Thoracic Society
  44. Society of Critical Care Medicine
  45. Pharmaceutical Research and Manufacturers of America
  46. AstraZeneca Pharmaceuticals
  47. Forest Pharmaceuticals

向作者/读者索取更多资源

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) can be caused by a wide variety of bacteria that originate from the patient flora or the health care environment. We review the medical and microbiology literature and the results of the SENTRY Antimicrobial Surveillance Program (1997-2008) to establish the pathogens most likely to cause HABP or VABP. In all studies, a consistent 6 organisms (Staphylococcus aureus [28.0%], Pseudomonas aeruginosa [21.8%], Klebsiella species [9.8%], Escherichia coli [6.9%], Acinetobacter species [6.8%], and Enterobacter species [6.3%]) caused similar to 80% of episodes, with lower prevalences of Serratia species, Stenotrophomonas maltophilia, and community-acquired pathogens, such as pneumococci and Haemophilus influenzae. Slight changes in the pathogen order were noted among geographic regions; Latin America had an increased incidence of nonfermentative gram-negative bacilli. In addition, VABP isolates of the same species had a mean of 5%-10% less susceptibility to frequently used extended-spectrum antimicrobials, and the rate of drug resistance among HABP and VABP pathogens has been increasing by 1% per year (2004-2008). In conclusion, the empirical treatment of HABP and VABP due to prevailing bacterial causes and emerging drug resistance has become more challenging and requires use of multidrug empirical treatment regimens for routine clinical practice. These facts have profound impact on the choices of comparison therapies to be applied in contemporary new drug clinical trials for pneumonia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据